• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by The Oncology Institute Inc.

    4/8/25 2:31:12 PM ET
    $TOI
    Medical/Nursing Services
    Health Care
    Get the next $TOI alert in real time by email
    SEC FORM D

    The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
    The reader should not assume that the information is accurate and complete.

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM D

    Notice of Exempt Offering of Securities

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated average burden
    hours per response: 4.00

    1. Issuer's Identity

    CIK (Filer ID Number) Previous Names
       None
    Entity Type
    0001799191
    DFP HEALTHCARE ACQUISITIONS CORP.
    X Corporation
       Limited Partnership
       Limited Liability Company
       General Partnership
       Business Trust
       Other (Specify)

    Name of Issuer
    Oncology Institute, Inc.
    Jurisdiction of Incorporation/Organization
    DELAWARE
    Year of Incorporation/Organization
    X Over Five Years Ago
       Within Last Five Years (Specify Year)
       Yet to Be Formed

    2. Principal Place of Business and Contact Information

    Name of Issuer
    Oncology Institute, Inc.
    Street Address 1 Street Address 2
    18000 STUDEBAKER RD SUITE 800
    City State/Province/Country ZIP/PostalCode Phone Number of Issuer
    CERRITOS CALIFORNIA 90703 562-735-3226

    3. Related Persons

    Last Name First Name Middle Name
    Virnich Daniel
    Street Address 1 Street Address 2
    18000 Studebaker Road, Suite 800
    City State/Province/Country ZIP/PostalCode
    Cerritos CALIFORNIA 90703
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Carter Robert
    Street Address 1 Street Address 2
    18000 Studebaker Road, Suite 800
    City State/Province/Country ZIP/PostalCode
    Cerritos CALIFORNIA 90703
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Castle Jeremy
    Street Address 1 Street Address 2
    18000 Studebaker Road, Suite 800
    City State/Province/Country ZIP/PostalCode
    Cerritos CALIFORNIA 90703
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Podnos Yale
    Street Address 1 Street Address 2
    18000 Studebaker Road, Suite 800
    City State/Province/Country ZIP/PostalCode
    Cerritos CALIFORNIA 90703
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Barasch Richard
    Street Address 1 Street Address 2
    18000 Studebaker Road, Suite 800
    City State/Province/Country ZIP/PostalCode
    Cerritos CALIFORNIA 90703
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Hively Brad
    Street Address 1 Street Address 2
    18000 Studebaker Road, Suite 800
    City State/Province/Country ZIP/PostalCode
    Cerritos CALIFORNIA 90703
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    McGeorge Anne
    Street Address 1 Street Address 2
    18000 Studebaker Road, Suite 800
    City State/Province/Country ZIP/PostalCode
    Cerritos CALIFORNIA 90703
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Johnson Karen
    Street Address 1 Street Address 2
    18000 Studebaker Road, Suite 800
    City State/Province/Country ZIP/PostalCode
    Cerritos CALIFORNIA 90703
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Kaushal Mohit
    Street Address 1 Street Address 2
    18000 Studebaker Road, Suite 800
    City State/Province/Country ZIP/PostalCode
    Cerritos CALIFORNIA 90703
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Pacala Mark
    Street Address 1 Street Address 2
    18000 Studebaker Road, Suite 800
    City State/Province/Country ZIP/PostalCode
    Cerritos CALIFORNIA 90703
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Ling Gabriel
    Street Address 1 Street Address 2
    18000 Studebaker Road, Suite 800
    City State/Province/Country ZIP/PostalCode
    Cerritos CALIFORNIA 90703
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    4. Industry Group

       Agriculture
    Banking & Financial Services
       Commercial Banking
       Insurance
       Investing
       Investment Banking
       Pooled Investment Fund
    Is the issuer registered as
    an investment company under
    the Investment Company
    Act of 1940?
       Yes    No
       Other Banking & Financial Services
       Business Services
    Energy
       Coal Mining
       Electric Utilities
       Energy Conservation
       Environmental Services
       Oil & Gas
       Other Energy
    Health Care
       Biotechnology
       Health Insurance
    X Hospitals & Physicians
       Pharmaceuticals
       Other Health Care
       Manufacturing
    Real Estate
       Commercial
       Construction
       REITS & Finance
       Residential
       Other Real Estate
      
    Retailing
      
    Restaurants
    Technology
       Computers
       Telecommunications
       Other Technology
    Travel
       Airlines & Airports
       Lodging & Conventions
       Tourism & Travel Services
       Other Travel
      
    Other

    5. Issuer Size

    Revenue Range OR Aggregate Net Asset Value Range
       No Revenues    No Aggregate Net Asset Value
       $1 - $1,000,000    $1 - $5,000,000
       $1,000,001 - $5,000,000    $5,000,001 - $25,000,000
       $5,000,001 - $25,000,000    $25,000,001 - $50,000,000
       $25,000,001 - $100,000,000    $50,000,001 - $100,000,000
       Over $100,000,000    Over $100,000,000
    X Decline to Disclose    Decline to Disclose
       Not Applicable    Not Applicable

    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

       Rule 504(b)(1) (not (i), (ii) or (iii))
       Rule 504 (b)(1)(i)
       Rule 504 (b)(1)(ii)
       Rule 504 (b)(1)(iii)
    X Rule 506(b)
       Rule 506(c)
       Securities Act Section 4(a)(5)
       Investment Company Act Section 3(c)
       Section 3(c)(1)    Section 3(c)(9)  
       Section 3(c)(2)    Section 3(c)(10)
       Section 3(c)(3)    Section 3(c)(11)
       Section 3(c)(4)    Section 3(c)(12)
       Section 3(c)(5)    Section 3(c)(13)
       Section 3(c)(6)    Section 3(c)(14)
       Section 3(c)(7)

    7. Type of Filing

    X New Notice Date of First Sale 2025-03-26    First Sale Yet to Occur
       Amendment

    8. Duration of Offering

    Does the Issuer intend this offering to last more than one year?
       Yes X No

    9. Type(s) of Securities Offered (select all that apply)

    X Equity    Pooled Investment Fund Interests
       Debt    Tenant-in-Common Securities
    X Option, Warrant or Other Right to Acquire Another Security    Mineral Property Securities
    X Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security    Other (describe)

    10. Business Combination Transaction

    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
       Yes X No

    Clarification of Response (if Necessary):

    11. Minimum Investment

    Minimum investment accepted from any outside investor $0 USD

    12. Sales Compensation

    Recipient
    Recipient CRD Number    None
    BTIG, LLC 122225
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    None None
    Street Address 1 Street Address 2
    350 Bush Street, 9th Floor
    City State/Province/Country ZIP/Postal Code
    San Francisco CALIFORNIA 94104
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
    X All States
       Foreign/non-US

    13. Offering and Sales Amounts

    Total Offering Amount $16,444,699 USD
    or    Indefinite
    Total Amount Sold $16,444,699 USD
    Total Remaining to be Sold $0 USD
    or    Indefinite

    Clarification of Response (if Necessary):

    14. Investors

      
    Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
    Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    14

    15. Sales Commissions & Finder's Fees Expenses

    Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

    Sales Commissions $1,085,606 USD
       Estimate
    Finders' Fees $0 USD
       Estimate

    Clarification of Response (if Necessary):

    16. Use of Proceeds

    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

    $0 USD
       Estimate

    Clarification of Response (if Necessary):

    Signature and Submission

    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

    Terms of Submission

    In submitting this notice, each issuer named above is:
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

    Issuer Signature Name of Signer Title Date
    Oncology Institute, Inc. /s/ Daniel Virnich Daniel Virnich Chief Executive Officer 2025-04-08

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

    * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


    Get the next $TOI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TOI

    DatePrice TargetRatingAnalyst
    11/25/2025$5.00Buy
    Needham
    7/23/2025$8.00Outperform
    Noble Capital Markets
    7/16/2025$6.00Buy
    B. Riley Securities
    5/15/2025$7.00Buy
    BTIG Research
    2/26/2024$2.50Buy
    Jefferies
    9/14/2022$7.00Buy
    Guggenheim
    8/15/2022$10.00Buy
    Jefferies
    More analyst ratings

    $TOI
    SEC Filings

    View All

    The Oncology Institute Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - Oncology Institute, Inc. (0001799191) (Filer)

    1/12/26 8:00:43 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    The Oncology Institute Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure

    8-K - Oncology Institute, Inc. (0001799191) (Filer)

    1/7/26 5:02:33 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    The Oncology Institute Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure

    8-K - Oncology Institute, Inc. (0001799191) (Filer)

    12/1/25 4:30:53 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    $TOI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Hively Brad bought $47,168 worth of shares (45,280 units at $1.04), increasing direct ownership by 7% to 712,033 units (SEC Form 4)

    4/A - Oncology Institute, Inc. (0001799191) (Issuer)

    4/28/25 7:20:14 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    Chief Executive Officer Virnich Daniel bought $23,584 worth of shares (22,640 units at $1.04), increasing direct ownership by 3% to 724,363 units (SEC Form 4)

    4 - Oncology Institute, Inc. (0001799191) (Issuer)

    3/28/25 5:50:27 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    Chief Medical Officer Podnos Yale bought $9,434 worth of shares (9,056 units at $1.04), increasing direct ownership by 13% to 79,049 units (SEC Form 4)

    4 - Oncology Institute, Inc. (0001799191) (Issuer)

    3/28/25 5:48:39 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    $TOI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The Oncology Institute Reaffirms 2025 Guidance and Provides Preliminary 2026 Outlook

    CERRITOS, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based oncology groups in the United States, today reaffirmed 2025 guidance and provided its preliminary 2026 outlook. 2026 Outlook For 2026, TOI anticipates that total revenue will be in the range of $630 million to $650 million, reflecting 28% growth from the midpoint of 2025 and 2026 guidance ranges, and including approximately $150 million of Capitation revenue in 2026. This expected top-line increase reflects continued expansion of delegated contracts in Florida, the annualized impact of strong volumes in the Dispensary segment during the se

    1/12/26 8:00:00 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    U.S. Neurology Associates Partners with M33 Growth to Transform Neurological Care

    DALLAS and BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- M33 Growth, a Boston-based venture and growth-stage investment firm, today announced its partnership with U.S. Neurology Associates ("USNA" or the "Company"), a physician services organization dedicated to transforming community-based neurology care. Through this partnership, USNA will serve neurology practices and their patients across a broad spectrum of neurological indications. Nitin Jain will serve as USNA's Chief Executive Officer and Brad Hively will serve as Chairman and co-founder. Prior to this role, Nitin Jain served as President of Value Based Care for U.S. Renal Care, and Brad Hively served as CEO of The Oncology Institute (

    1/9/26 4:45:26 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    The Oncology Institute Announces Leadership Promotions

    Rakesh Panda appointed Chief Information Officer Nolan Mariano appointed Chief People Officer CERRITOS, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) announced today the promotions of Rakesh Panda to Chief Information Officer and Nolan Mariano to Chief People Officer. These promotions reinforce TOI's continued focus on leading the way in value-based cancer care through further development of our technology-enabled care delivery platform as well as strengthening our mission-oriented culture supported by strong leadership. Rakesh Panda has more than 25 years of experience across IT, digital transformation, cybersecurity, and enterprise software develo

    1/9/26 8:00:00 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    $TOI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Stolper Mark

    3 - Oncology Institute, Inc. (0001799191) (Issuer)

    1/12/26 4:57:19 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    Amendment: Chief Financial Officer Carter Robert Ross disposed of $895 worth of shares (244 units at $3.67), decreasing direct ownership by 0.10% to 235,125 units (SEC Form 4)

    4/A - Oncology Institute, Inc. (0001799191) (Issuer)

    1/6/26 4:30:02 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    Chief Financial Officer Carter Robert Ross sold $879 worth of shares (247 units at $3.56), decreasing direct ownership by 0.10% to 235,122 units (SEC Form 4)

    4 - Oncology Institute, Inc. (0001799191) (Issuer)

    1/5/26 5:04:59 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    $TOI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham initiated coverage on The Oncology Institute with a new price target

    Needham initiated coverage of The Oncology Institute with a rating of Buy and set a new price target of $5.00

    11/25/25 8:00:05 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    Noble Capital Markets initiated coverage on The Oncology Institute with a new price target

    Noble Capital Markets initiated coverage of The Oncology Institute with a rating of Outperform and set a new price target of $8.00

    7/23/25 9:21:53 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    B. Riley Securities initiated coverage on The Oncology Institute with a new price target

    B. Riley Securities initiated coverage of The Oncology Institute with a rating of Buy and set a new price target of $6.00

    7/16/25 7:58:29 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    $TOI
    Leadership Updates

    Live Leadership Updates

    View All

    The Oncology Institute Announces Addition of Board Member Mark Stolper

    CERRITOS, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced that Mark Stolper has joined the Board of Directors, effective January 2, 2026. Mr. Stolper brings significant public markets, financial and operational leadership experience to The Oncology Institute's board. Mr. Stolper serves as Executive Vice President and Chief Financial Officer of RadNet, Inc. (NASDAQ:RDNT), a position he has held since 2004. Mr. Stolper has also been a member of the Board of Directors of various publicly traded and privately held healthcare companies, including 21st Century Oncolog

    1/5/26 8:30:00 AM ET
    $RDNT
    $TOI
    Medical Specialities
    Health Care
    Medical/Nursing Services

    The Oncology Institute Announces Resignation of Board Member Gabe Ling

    CERRITOS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced that Gabe Ling has resigned from the Board of Directors, effective December 1, 2025. A formal search process has been initiated to add new independent directors with complementary healthcare, clinical, and value-based care expertise. "On behalf of the Board of Directors, I want to thank Gabe for his service during an important chapter in The Oncology Institute's development," said Anne McGeorge, Chairman of the Board. "We appreciate the contributions he made throughout his time on the Board and the valua

    12/1/25 8:30:00 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    The Oncology Institute Names Kristin England as Chief Administrative Officer

    CERRITOS, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI"), one of the largest value-based oncology groups in the United States, announced today that Kristin England has joined the organization as Chief Administrative Officer (CAO), effective July 7, 2025. In this newly established role, England will oversee Enterprise Central Business Operations and Technology Strategy and Enablement across TOI's expanding national footprint. England brings over two decades of leadership experience in healthcare management and operations, most recently serving as a senior executive within McKesson's US Oncology Network. There, she led high-performing teams focus

    7/14/25 4:05:25 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    $TOI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by The Oncology Institute Inc.

    SC 13D/A - Oncology Institute, Inc. (0001799191) (Subject)

    8/20/24 8:20:55 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    SEC Form SC 13D/A filed by The Oncology Institute Inc. (Amendment)

    SC 13D/A - Oncology Institute, Inc. (0001799191) (Subject)

    1/2/24 5:06:50 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    SEC Form SC 13G/A filed by The Oncology Institute Inc. (Amendment)

    SC 13G/A - Oncology Institute, Inc. (0001799191) (Subject)

    7/10/23 10:20:11 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    $TOI
    Financials

    Live finance-specific insights

    View All

    The Oncology Institute Reports Third Quarter 2025 Financial Results and Increases Full Year 2025 Guidance

    CERRITOS, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its three months ended September 30, 2025 and updated its full year 2025 guidance. Recent Operational Highlights Fee-for-service revenue growth of 13% over Q3 2024, driven by continued organic growth performance in Florida and Oregon.Retail Pharmacy and Dispensary set fill records, contributing $75.9 million in revenue and $12.8 million in gross profit in Q3. Signed several new in-network MSO providers in the Florida market and opened our new TOI pharmacy

    11/13/25 4:05:00 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    The Oncology Institute Announces Third Quarter 2025 Earnings Release Date and Conference Call

    CERRITOS, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI),  a pioneer in value-based community oncology care, today announced that the company will release its third quarter 2025 financial results after the market close on Thursday, November 13, 2025, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 1

    10/22/25 4:47:31 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    The Oncology Institute Reports Second Quarter 2025 Financial Results and Reaffirms Full Year 2025 Guidance

    CERRITOS, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its three months ended June 30, 2025. Daniel Virnich, CEO of TOI, commented, "We delivered another strong quarter with over 20% year-over-year revenue growth. This was driven by exceptional performance in our pharmacy business, which grew over 40% year-over-year, as well as the addition of over 50,000 new capitated lives to our value-based business. We are also in the process of expanding our partnership into new geographic regions of Florida with a major

    8/13/25 4:05:00 PM ET
    $TOI
    Medical/Nursing Services
    Health Care